Haemonetics FY27 Q1 adjusted EPS rises 3.6% to $1.14; revenue climbs 5.6% to $339.4 million

Reuters2026/08/06 10:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Haemonetics posted Q1 fiscal 2027 revenue of $339.4 million, up 5.6% from a year earlier.
GAAP net income slipped to $33 million while GAAP diluted EPS rose to $0.72.
Adjusted diluted EPS increased 3.6% to $1.14; GAAP operating income climbed 6.7% to $57.5 million.
Operating cash flow rose to $52.3 million; free cash flow increased to $39.1 million.
Raised fiscal 2027 reported revenue growth outlook to 5%-8% from 4%-7%; organic revenue growth seen at 4%-7% from 3%-6%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Haemonetics Corporation published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Haemonetics FY27 Q1 adjusted EPS rises 3.6% to $1.14; revenue climbs 5.6% to $339.4 million

You may also like

Crypto prices